Grifols’ Tavlesse (fostamatinib) Receives NICE Recommendation for the Treatment of Refractory Chronic Immune Thrombocytopenia
Shots:
- The NICE has recommended Tavlesse for chronic ITP in adult patients. Tavlesse is available in the US under the brand name Tavalisse
- Grifols gets an exclusive right to fostamatinib in chronic ITP in EU Turkey, Middle East, North Africa & CIS countries under collaboration with Rigel. The company continues its phased EU roll-out of the treatment & which is also available in Czech Republic & other countries
- The company collaborated closely with UK healthcare professionals & patient organizations to address the unmet need for patients with refractory ITP and the value of Tavlesse. The company will strengthen its industry-leading portfolio through in-licensing agreements for existing & emerging diseases, benefits patients, provide additional therapies to healthcare providers
Ref: Grifols| Image: Grifols
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
